These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 14607997)

  • 1. Intravenous iron as adjuvant therapy: a two-edged sword?
    Cavill I
    Nephrol Dial Transplant; 2003 Nov; 18 Suppl 8():viii24-8. PubMed ID: 14607997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran--a comparison of two products.
    McCarthy JT; Regnier CE; Loebertmann CL; Bergstralh EJ
    Am J Nephrol; 2000; 20(6):455-62. PubMed ID: 11146312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous iron supplementation in the anaemia of renal and cardiac failure--a double-edged sword?
    Slotki I
    Nephrol Dial Transplant; 2005 Jul; 20 Suppl 7():vii16-23. PubMed ID: 16024827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute injury with intravenous iron and concerns regarding long-term safety.
    Bishu K; Agarwal R
    Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S19-23. PubMed ID: 17699372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies for iron supplementation: oral versus intravenous.
    Macdougall IC
    Kidney Int Suppl; 1999 Mar; 69():S61-6. PubMed ID: 10084288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Erythropoetin and iron preparations in the treatment of anemia in patients with chronic kidney disease of stage III-IV in systemic diseases].
    Kozlovskaia LV; Milovanov IuS; Nikolaev AIu; Milovanova LIu
    Ter Arkh; 2007; 79(6):30-4. PubMed ID: 17684963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: a meta-analysis.
    Susantitaphong P; Alqahtani F; Jaber BL
    Am J Nephrol; 2014; 39(2):130-41. PubMed ID: 24513913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety aspects of parenteral iron in patients with end-stage renal disease.
    Sunder-Plassmann G; Hörl WH
    Drug Saf; 1997 Oct; 17(4):241-50. PubMed ID: 9352960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia.
    Baldamus C; Krivoshiev S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A
    Adv Ther; 2008 Nov; 25(11):1215-28. PubMed ID: 18931828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [How do we need to maintain the iron status in dialyzed patients treated with erythropoesis stimulating agents].
    Kes P; Basić-Jukići N; Jurić I
    Acta Med Croatica; 2009 Sep; 63 Suppl 1():54-61. PubMed ID: 20232552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The benefits of IV iron therapy in treating anemia in patients with renal disease and comorbid cardiovascular disease.
    Singh AK; Hertello P
    Nephrol Nurs J; 2005; 32(2):199-206; quiz 207-8. PubMed ID: 15889804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous iron therapy in renal failure: friend and foe?
    Afzali B; Goldsmith DJ
    J Nephrol; 2004; 17(4):487-95. PubMed ID: 15372409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on clinical practice recommendations and new therapeutic modalities for treating anemia in patients with chronic kidney disease.
    Grabe DW
    Am J Health Syst Pharm; 2007 Jul; 64(13 Suppl 8):S8-14; quiz S23-5. PubMed ID: 17591995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current management of anemia in adult hemodialysis patients with end-stage renal disease.
    Frankenfield DL; Johnson CA
    Am J Health Syst Pharm; 2002 Mar; 59(5):429-35. PubMed ID: 11887409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current issues in erythropoietin therapy of renal anemia].
    Zakar G
    Lege Artis Med; 2007 Oct; 17(10):667-73. PubMed ID: 19227596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal treatment of renal anaemia (OPTA): improving the efficacy and efficiency of renal anaemia therapy in haemodialysis patients receiving intravenous epoetin.
    Hörl WH; Vanrenterghem Y; Canaud B; Mann J; Teatini U; Wanner C; Wikström B
    Nephrol Dial Transplant; 2005 May; 20 Suppl 3():iii25-32. PubMed ID: 15824127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer-related anaemia requires higher doses of epoetin alfa than chronic renal failure replacement therapy.
    Itri LM
    Nephrol Dial Transplant; 2001 Dec; 16(12):2289-93. PubMed ID: 11733616
    [No Abstract]   [Full Text] [Related]  

  • 18. Administration of Epoetin alfa. Case study of the anemic patient.
    Cutler M
    ANNA J; 1997 Aug; 24(4):459-65; quiz 466. PubMed ID: 9325701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epoetin alfa. A review of its clinical efficacy in the management of anaemia associated with renal failure and chronic disease and its use in surgical patients.
    Dunn CJ; Wagstaff AJ
    Drugs Aging; 1995 Aug; 7(2):131-56. PubMed ID: 7579784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An open-label, randomized, multicenter, controlled study of epoetin alfa for the treatment of anemia of chronic kidney disease in the long term care setting.
    Patel M; Thimons DG; Winston JL; Langholff W; McGowan T
    J Am Med Dir Assoc; 2012 Mar; 13(3):244-8. PubMed ID: 21450214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.